These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38588410)

  • 1. PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways.
    Yang J; Wang L; Byrnes JR; Kirkemo LL; Driks H; Belair CD; Aguilar OA; Lanier LL; Wells JA; Fong L; Blelloch R
    Cancer Immunol Res; 2024 May; 12(5):575-591. PubMed ID: 38588410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
    Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
    Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse PVRIG Has CD8
    Murter B; Pan X; Ophir E; Alteber Z; Azulay M; Sen R; Levy O; Dassa L; Vaknin I; Fridman-Kfir T; Salomon R; Ravet A; Tam A; Levin D; Vaknin Y; Tatirovsky E; Machlenkin A; Pardoll D; Ganguly S
    Cancer Immunol Res; 2019 Feb; 7(2):244-256. PubMed ID: 30659055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.
    Murakami K; Ganguly S
    Front Immunol; 2024; 15():1441730. PubMed ID: 39156900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
    Stamm H; Klingler F; Grossjohann EM; Muschhammer J; Vettorazzi E; Heuser M; Mock U; Thol F; Vohwinkel G; Latuske E; Bokemeyer C; Kischel R; Dos Santos C; Stienen S; Friedrich M; Lutteropp M; Nagorsen D; Wellbrock J; Fiedler W
    Oncogene; 2018 Sep; 37(39):5269-5280. PubMed ID: 29855615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
    Hansen K; Kumar S; Logronio K; Whelan S; Qurashi S; Cheng HY; Drake A; Tang M; Wall P; Bernados D; Leung L; Ophir E; Alteber Z; Cojocaru G; Galperin M; Frenkel M; White M; Hunter J; Liang SC; Kotturi MF
    Cancer Immunol Immunother; 2021 Dec; 70(12):3525-3540. PubMed ID: 33903974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
    Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
    J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
    Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
    J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors.
    Li Y; Zhang Y; Cao G; Zheng X; Sun C; Wei H; Tian Z; Xiao W; Sun R; Sun H
    J Hematol Oncol; 2021 Jun; 14(1):100. PubMed ID: 34174928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CD112R/CD112 axis: a breakthrough in cancer immunotherapy.
    Zeng T; Cao Y; Jin T; Tian Y; Dai C; Xu F
    J Exp Clin Cancer Res; 2021 Sep; 40(1):285. PubMed ID: 34507594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIGIT in cancer immunotherapy.
    Chauvin JM; Zarour HM
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia.
    Li J; Whelan S; Kotturi MF; Meyran D; D'Souza C; Hansen K; Liang S; Hunter J; Trapani JA; Neeson PJ
    Haematologica; 2021 Dec; 106(12):3115-3124. PubMed ID: 33147937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models.
    Xue H; Zhang Z; Li L; Zhu C; Fei K; Sha H; Wu Z; Lin X; Wang F; Zhou S; Deng X; Li Y; Chen B; Xiong Y; Chen K
    Cancer Immunol Immunother; 2024 Mar; 73(5):81. PubMed ID: 38554184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
    Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
    Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
    Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
    Front Immunol; 2018; 9():2821. PubMed ID: 30555485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.
    Stanietsky N; Simic H; Arapovic J; Toporik A; Levy O; Novik A; Levine Z; Beiman M; Dassa L; Achdout H; Stern-Ginossar N; Tsukerman P; Jonjic S; Mandelboim O
    Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17858-63. PubMed ID: 19815499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIGIT-Fc Promotes Antitumor Immunity.
    Shen X; Fu W; Wei Y; Zhu J; Yu Y; Lei C; Zhao J; Hu S
    Cancer Immunol Res; 2021 Sep; 9(9):1088-1097. PubMed ID: 34244300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.